Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
US8642040B2 · kind B2 · utility
23Cited by
11References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2007 |
| Grant date | Feb 4, 2014 |
| Priority date | — |
| Expiry date | Jun 26, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.